Look for Stuart Therapeutics this fall at the annual
BioFlorida, BIO-Europe, and OIS conferences

Welcome To Stuart Therapeutics

Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that offers improvements in health outcomes for a wide variety of medical and veterinary conditions.

PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property developed by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.

The initial product under development that takes advantage of PolyCol is ST-100, the first therapeutic for dry eye syndrome that addresses both the immediate painful symptoms, as well as the underlying inflammatory causes.

Latest News

04 Oct. 2018
Stuart Therapeutics Announces Corneal Epithelial Healing and Organization Pre-Clinical Results for its Potential Dry Eye Therapeutic

October 4th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol).  The company announced additional important results from its mouse eye wound tests.  Previous results showed statistically significant results

Read More
17 Sep. 2018
Stuart Therapeutics Announces Important Pre-Clinical Results for ST-100

September 17th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol).  Mouse eye wound tests conducted at the University of Louisville demonstrated rapid, high quality healing of corneal wounds,

Read More
12 Sep. 2018
Stuart Therapeutics has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference

September 12th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference, October 14th – 16th in Ft. Lauderdale, Florida.  The BioPitch competition annually selects 15 companies

Read More